Teva Pharmaceutical Industries (TEVA) Capital Expenditures: 2009-2025
Historic Capital Expenditures for Teva Pharmaceutical Industries (TEVA) over the last 16 years, with Sep 2025 value amounting to $136.0 million.
- Teva Pharmaceutical Industries' Capital Expenditures fell 8.11% to $136.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $488.0 million, marking a year-over-year negligible change of negligibly%. This contributed to the annual value of $498.0 million for FY2024, which is 5.32% down from last year.
- Latest data reveals that Teva Pharmaceutical Industries reported Capital Expenditures of $136.0 million as of Q3 2025, which was up 41.67% from $96.0 million recorded in Q2 2025.
- In the past 5 years, Teva Pharmaceutical Industries' Capital Expenditures ranged from a high of $157.0 million in Q1 2022 and a low of $96.0 million during Q2 2025.
- Over the past 3 years, Teva Pharmaceutical Industries' median Capital Expenditures value was $127.0 million (recorded in 2025), while the average stood at $125.7 million.
- In the last 5 years, Teva Pharmaceutical Industries' Capital Expenditures increased by 22.13% in 2023 and then fell by 18.49% in 2024.
- Quarterly analysis of 5 years shows Teva Pharmaceutical Industries' Capital Expenditures stood at $153.0 million in 2021, then decreased by 7.19% to $142.0 million in 2022, then declined by 16.20% to $119.0 million in 2023, then rose by 8.40% to $129.0 million in 2024, then fell by 8.11% to $136.0 million in 2025.
- Its Capital Expenditures was $136.0 million in Q3 2025, compared to $96.0 million in Q2 2025 and $127.0 million in Q1 2025.